Back
Geron Corporation (GERN)
BiotechnologyGERN · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$1.52
−1.93%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-0.13
ROE
-27.1%
Gross margin
61.0%
Debt/Equity
0.53x
Revenue growth
30.9%
Geron Corporation — company intelligence
Earnings surprises
Q2 2026$-0.02 vs $-0.01 est-117.4%
Q1 2026$-0.01 vs $-0.02 est+52.6%
Q4 2025$-0.02 vs $-0.03 est+38.1%
Q3 2025$-0.03 vs $-0.03 est+11.0%
Analyst consensus · 11 analysts
9 Buy2 Hold0 Sell
Updated Aug 12, 2026
Insider activity · 90 days
1 buy0 sellsnet +6,103 shares
Spiegel Robert J.Buy 6,103 · Jun 30, 2026
Recent SEC filings
8-K — Material event reportAug 6, 2026
10-Q — Quarterly reportAug 5, 2026
4 — Insider transaction reportJul 1, 2026
Latest news
Geron Corp.: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis — SeekingAlpha · 1w ago
Geron (NASDAQ:GERN) Falls After Mixed Q2 Results; Revenue Beats but Loss Wider Than Expected — ChartMill · 2w ago
Geron Corporation (GERN) Q2 2026 Earnings Call Transcript — SeekingAlpha · 2w ago
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Yahoo · Jul 22, 2026
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026 — Yahoo · Jul 22, 2026
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.